Prostaglandin E2 attenuates SR141716A-precipitated withdrawal in tetrahydrocannabinol-dependent mice

被引:21
作者
Anggadiredja, K
Yamaguchi, T
Tanaka, H
Shoyama, Y
Watanabe, S
Yamamoto, T
机构
[1] Kyushu Univ, Grad Sch Pharmaceut Sci, Dept Pharmacol, Higashi Ku, Fukuoka 8128582, Japan
[2] Kyushu Univ, Grad Sch Pharmaceut Sci, Dept Med Plant Breeding, Fukuoka 8128582, Japan
[3] Kyushu Univ, Grad Sch Pharmaceut Sci, Dept Med Resources Regulat, Fukuoka 8128582, Japan
关键词
precipitated withdrawal; SR141716A; Delta(8)-tetrahydrocannabinol; prostaglandin E-2; diclofenac; mouse;
D O I
10.1016/S0006-8993(02)04169-0
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The present study aimed to clarify the role of the arachidonic acid cascade in mediating the expression of withdrawal signs in cannabinoid-dependent mice. Mice were injected with Delta(8)-tetrahydrocannabinol (THC) at 20 mg/kg (i.p.) every 12 h, 11 times. When SR141716A, a specific cannabinoid CBI receptor antagonist, at 10 mg/kg (i.p.) was given 4 It after the last THC injection, withdrawal signs such as forepaw licking, facial preening, grooming, forepaw tremor, head shakes and weight loss were clearly observed. PGE(2) at 0.1, 1.0 and 3.2 mug (per animal; i.c.v.) given prior to SR141716A (10 mg/kg, i.p.) dose-dependently decreased the number of forepaw licking, facial preening, grooming and forepaw tremor episodes. Instead of SR141716A, a cyclooxygenase inhibitor diclofenac at 10 mg/kg (i.p.) also precipitated these withdrawal signs. The results suggest that the expression of THC withdrawal is due to a decrease in prostaglandin levels through inactivation of the arachidonic acid cascade in the brain. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:47 / 53
页数:7
相关论文
共 37 条
[1]   CANNABINOID PRECIPITATED WITHDRAWAL BY THE SELECTIVE CANNABINOID RECEPTOR ANTAGONIST, SR 141716A [J].
ACETO, MD ;
SCATES, SM ;
LOWE, JA ;
MARTIN, BR .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1995, 282 (1-3) :R1-R2
[2]   Effects of the cannabinoid CB1 receptor antagonist, SR141716A, after Δ9-tetrahydrocannabinol withdrawal [J].
Beardsley, PM ;
Martin, BR .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2000, 387 (01) :47-53
[3]  
BHATTACHARYA SK, 1986, PSYCHOPHARMACOLOGY, V90, P499
[4]  
Cook SA, 1998, J PHARMACOL EXP THER, V285, P1150
[5]  
DEWEY WL, 1986, PHARMACOL REV, V38, P151
[6]  
EXNER HJ, 1995, N-S ARCH PHARMACOL, V351, P46
[7]  
FELDER CC, 1992, MOL PHARMACOL, V42, P838
[8]   Abstinence symptoms following smoked marijuana in humans [J].
Haney, M ;
Ward, AS ;
Comer, SD ;
Foltin, RW ;
Fischman, MW .
PSYCHOPHARMACOLOGY, 1999, 141 (04) :395-404
[9]   Abstinence symptoms following oral THC administration to humans [J].
Haney, M ;
Ward, AS ;
Comer, SD ;
Foltin, RW ;
Fischman, MW .
PSYCHOPHARMACOLOGY, 1999, 141 (04) :385-394
[10]   EVALUATION OF REINFORCING CAPABILITY OF DELTA-9-TETRAHYDROCANNABINOL IN RHESUS-MONKEYS [J].
HARRIS, RT ;
WATERS, W ;
MCLENDON, D .
PSYCHOPHARMACOLOGIA, 1974, 37 (01) :23-29